Pathological study of Baicalin combined with Berberine on two animal models of non-alcoholic steatohepatitis
XU Chang1 MA Zhijie2 HUANG Feng3 ZHONG Xiaosong1
1.Clinical Gene and Cell Engineering Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;
2.Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;
3.Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China
Abstract：Objective To investigate the effect of Baicalin combined with Berberine on non-alcoholic steatohepatitis (NASH) in two animal models from the pathological point of view. Methods 40 SD rats and 40 C57BL/6 mice aged 6 weeks were divided into four groups according to random number table method: normal control group, NASH model group, Berberine group, Baicalin + Berberine group, 10 rats (or mice) in each group. In addition to normal control group, the other three groups prepared SD rats NASH model induced by high fat diet and C57BL/6 mice NASH model induced by methionine-choline deficiency diet. Berberine group was given Berberine by gavage, Baicalin + Berberine group was given Baicalin and Berberine by gavage. The rats were taken after 8 weeks, and the mice were taken after 2 weeks. Paraffin sections of liver tissue were stained with HE, frozen sections were stained with oil red O. After light microscopy, non-alcoholic fatty liver disease activity scale (NAS) was used to evaluate NASH in each group. Results The scores of hepatic steatosis, intralobular inflammation, hepatocyte balloon-like degeneration and total NAS in NASH model group were significantly higher than those in normal control group of two animal models (P < 0.01). The scores of hepatic steatosis, intralobular inflammation, hepatocyte balloon-like degeneration and NAS in Berberine group and Baicalin + Berberine group were significantly lower than those in NASH model group of two animal models (P < 0.05 or P < 0.01). Conclusion Baicalin and Berberine can significantly inhibit the occurrence and development of pathological changes in NASH. They have certain intervention effect on NASH.
续畅1 马致洁2 黄凤3 钟晓松1. 黄芩苷联合小檗碱干预非酒精性脂肪性肝炎两种动物模型的病理学研究[J]. 中国医药导报, 2019, 16(24): 7-10,14.
XU Chang1 MA Zhijie2 HUANG Feng3 ZHONG Xiaosong1. Pathological study of Baicalin combined with Berberine on two animal models of non-alcoholic steatohepatitis. 中国医药导报, 2019, 16(24): 7-10,14.
[1] European Association for the Study of the Liver（EASL），European Association for the Study of Diabetes（EASD），European Association for the Study of Obesity（EASO）. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease [J]. Diabetologia，2016，59（6）：1121-1140.
[2] Eslam M，George J. Genetic and epigenetic mechanisms of NASH [J]. Hepatol Int，2016，10（3）：394-406.
[3] Laish I，Mannasse-Green B，Hadary R，et al. Telomere dysfunction in nonalcoholic fatty liver disease and cryptogenic cirrhosis [J]. Cytogenet Genome Res，2016，150（2）：93-99.
[4] Chow MD，Lee YH，Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]. Mol Aspects Med，2017，56（1）：34-44.
[5] Lee GS，Yan JS，Ng RK，et al. Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury [J]. J Lipid Res，2007，48（8）：1885-1896.
[6] 续畅，刘泽洲，许可嘉，等.高脂及MCD饮食诱导非酒精性脂肪性肝炎动物模型的比较[J].现代生物医学进展，2014，14（18）：3451-3455.
[7] Kleiner DE，Brunt EM，Van Natta M，et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease [J]. Hepatology，2005，41（6）：1313-1321.
[8] Liu CS，Zheng YR， Zhang YF，et al. Research progress on berberine with a special focus on its oral bioavailability [J]. Fitoterapia，2016，109（1）：274-282.
[9] Chang W，Chen L，Hatch GM. Berberine as a therapy for type 2 diabetes and its complications：from mechanism of action to clinical studies [J]. Biochem Cell Biol，2015，93（5）：479-486.
[10] Zhou H，FengL，Xu F，et al. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages：a new mechanism linking berberine to insulin resistance improvement [J]. Biomed Pharmacother，2017，89（1）：864-874.
[11] 续畅，刘学龙，倪建腾，等.盐酸小檗碱片治疗非酒精性脂肪性肝病疗效的Meta分析[J].中国药房，2015，26（30）：4232-4235.
[12] Luan Y，Sun C，Wang J，et al. Baicalin attenuates myocardial ischemia-reperfusion injury through Akt/NF-κB pathway [J]. J Cell Biochem，2019，120（3）：3212-3219.
[13] Ma W，Liu X，Du W. Baicalin induces apoptosis in SW480 cells through downregulation of the SP1 transcription factor [J]. Anticancer Drugs，2019，30（2）：153-158.
[14] Oo A，Teoh BT，Sam SS，et al. Baicalein and baicalin as Zika virus inhibitors [J]. Arch Virol，2019，164（2）：585-593.
[15] Liu Y，Jia L，Min D，et al. Baicalin inhibits proliferation and promotes apoptosis of vascular smooth muscle cells by regulating the MEG3/p53 pathway following treatment with ox-LDL [J]. Int J Mol Med，2019，43（2）：901-913.
[16] Shi J，Wu G，Zou X，et al. Enteral baicalin，a flavone glycoside，reduces indicators of cardiac surgery-associated acute kidney injury in rats [J]. Cardiorenal Med，2019，9（1）：31-40.
[17] Yang S，Zhang Y，Shen F，et al. The flavonoid baicalin improves glucose metabolism by targeting the PH domain of AKT and activating AKT/GSK3β phosphorylation [J]. FEBS Lett，2019，593（2）：175-186.
[18] Luo J，Kong H，Zhang M，et al. Novel carbon dots-derived from radix puerariaecarbonisata significantly improve the solubility and bioavailability of baicalin [J]. J Biomed Nanotechnol，2019，15（1）：151-161.
[19] 续畅，王允亮，张慧芹，等.葛根芩连汤对高脂饮食诱导大鼠非酒精性脂肪性肝炎的影响[J].世界华人消化杂志，2014，22（4）：546-552.
[20] 续畅，钟萌，马致洁，等.葛根芩连汤的现代研究进展[J].吉林中医药，2015，35（6）：629-632.
2019, Vol. 16 
京公网安备 11010502046598号